See more : The Becker Milk Company Limited (BEK-B.TO) Income Statement Analysis – Financial Results
Complete financial analysis of BridgeBio Pharma, Inc. (BBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BridgeBio Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Flutter Entertainment plc (FLUT) Income Statement Analysis – Financial Results
- Dongwu Cement International Limited (0695.HK) Income Statement Analysis – Financial Results
- Auden Techno Corp. (3138.TW) Income Statement Analysis – Financial Results
- Bounce Mobile Systems, Inc. (BNCM) Income Statement Analysis – Financial Results
- Isramco Negev 2 Limited Partnership (ISRA.TA) Income Statement Analysis – Financial Results
BridgeBio Pharma, Inc. (BBIO)
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 9.30M | 77.65M | 69.72M | 8.25M | 40.56M | 0.00 | 0.00 |
| Cost of Revenue | 2.45M | 3.43M | 3.11M | 3.09M | 2.50M | 0.00 | 260.00K |
| Gross Profit | 6.86M | 74.21M | 66.60M | 5.16M | 38.06M | 0.00 | -260.00K |
| Gross Profit Ratio | 73.71% | 95.58% | 95.53% | 62.57% | 93.84% | 0.00% | 0.00% |
| Research & Development | 455.71M | 402.90M | 454.14M | 337.05M | 209.95M | 140.07M | 30.56M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 145.68M | 94.35M | 43.59M | 13.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 150.59M | 143.19M | 192.21M | 145.68M | 94.35M | 43.59M | 13.30M |
| Other Expenses | 7.93M | 100.45M | 35.82M | 1.63M | -1.21M | -1.29M | 0.00 |
| Operating Expenses | 614.23M | 546.09M | 646.35M | 482.73M | 304.30M | 183.66M | 43.86M |
| Cost & Expenses | 616.67M | 546.09M | 646.35M | 482.73M | 306.80M | 183.66M | 43.86M |
| Interest Income | 18.04M | 7.54M | 1.13M | 4.02M | 8.92M | 2.00M | 39.00K |
| Interest Expense | 81.29M | 80.44M | 46.78M | 36.66M | 8.77M | 2.55M | 13.00K |
| Depreciation & Amortization | 6.49M | 6.77M | 5.84M | 3.09M | 859.00K | 245.00K | 260.00K |
| EBITDA | -565.47M | -397.44M | -533.83M | -465.75M | -279.82M | -183.42M | -43.56M |
| EBITDA Ratio | -6,078.34% | -455.49% | -774.11% | -5,683.51% | -688.87% | 0.00% | 0.00% |
| Operating Income | -607.37M | -471.87M | -579.75M | -474.48M | -266.24M | -183.66M | -43.86M |
| Operating Income Ratio | -6,528.75% | -607.71% | -831.58% | -5,751.99% | -656.41% | 0.00% | 0.00% |
| Total Other Income/Expenses | -45.88M | 27.55M | -9.82M | -31.01M | -22.35M | 14.21M | 26.00K |
| Income Before Tax | -653.25M | -484.65M | -586.45M | -505.49M | -288.59M | -169.45M | -43.83M |
| Income Before Tax Ratio | -7,021.94% | -624.17% | -841.20% | -6,127.87% | -711.50% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 9.31M | 52.84M | -21.56M | -28.15M | 16.76M | -13.49M |
| Net Income | -643.20M | -493.96M | -639.30M | -483.93M | -260.44M | -130.75M | -30.57M |
| Net Income Ratio | -6,913.92% | -636.16% | -917.00% | -5,866.47% | -642.10% | 0.00% | 0.00% |
| EPS | -3.95 | -3.35 | -4.43 | -4.10 | -2.48 | -1.42 | -0.33 |
| EPS Diluted | -3.95 | -3.35 | -4.43 | -4.10 | -2.48 | -1.42 | -0.33 |
| Weighted Avg Shares Out | 162.79M | 147.47M | 144.36M | 118.00M | 105.10M | 92.33M | 92.33M |
| Weighted Avg Shares Out (Dil) | 162.79M | 147.47M | 144.36M | 118.00M | 105.10M | 92.33M | 92.33M |
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Source: https://incomestatements.info
Category: Stock Reports